Immune · α-MSH tripeptide · Compounded 503A
KPV: the anti-inflammatory tail of α-MSH.
KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (α-MSH). It retains α-MSH's anti-inflammatory activity without the melanogenic effects of the full molecule — making it one of the smallest peptides with substantive immunomodulatory pharmacology.
What KPV is
KPV is the C-terminal three amino acids of α-MSH (alpha-melanocyte-stimulating hormone). α-MSH itself is a potent endogenous anti-inflammatory peptide produced from the POMC precursor — but it also drives pigmentation.
Isolating the C-terminal KPV tripeptide preserves the anti-inflammatory activity while removing the melanogenic effect — yielding a smaller, more selective immunomodulator.
It is investigational and dispensed through compounded 503A pharmacies for off-label use in inflammatory gut, skin, and immune indications. Its small size allows oral, topical, and injection routes.
How it works
KPV inhibits NF-κB activation — the master transcription factor that drives expression of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β). This suppresses inflammation at a foundational signaling node.
In the gut, KPV downregulates inflammatory cytokine production in intestinal epithelial cells and modulates the immune response that drives IBD-spectrum inflammation.
KPV also modulates mast cell activity, reducing histamine release and downstream inflammatory cascades — relevant for mast cell activation syndromes and chronic inflammatory skin conditions.
What patients use it for
Gut inflammation
Most-studied application — KPV downregulates inflammatory cytokines in intestinal epithelium, with preclinical efficacy in IBD models.
Inflammatory skin conditions
Topical KPV has been investigated for atopic dermatitis, psoriasis, and chronic wound inflammation — leveraging α-MSH's skin anti-inflammatory heritage.
Mast cell modulation
By dampening mast cell activity, KPV has potential application in mast cell activation syndrome (MCAS) and histamine-driven conditions.
Wound healing
α-MSH and its fragments support wound healing — KPV preserves this activity in a much smaller, more stable molecule.
Evidence summary
Kannengiesser K et al. (Inflammatory Bowel Diseases, 2008) demonstrated KPV's anti-inflammatory efficacy in models of intestinal inflammation, reducing cytokine production and disease severity.
Brzoska T et al. (Endocrine Reviews, 2008) reviewed the α-MSH / KPV anti-inflammatory mechanism and its therapeutic potential across inflammatory conditions.
Dalmasso G et al. (Gastroenterology, 2008) showed KPV is taken up by intestinal epithelial cells via PEPT1 and exerts anti-inflammatory activity directly in the gut mucosa.
Honest framing: solid preclinical anti-inflammatory mechanism, particularly in gut models. Human RCT data is limited.
Dosing and clinical context
General clinical context only. Kindr Health physicians determine the appropriate dose and protocol for each patient based on history and labs. This is not a prescription or dosing recommendation.
Oral capsule (often paired with BPC-157 for gut indications), topical cream (for skin indications), or subcutaneous injection.
Course-based use, typically 4–8 weeks targeted at a specific inflammatory indication.
Compounded KPV from licensed 503A pharmacies is the typical U.S. dispensing pathway. Not FDA-approved.
Safety and contraindications
Generally well-tolerated. Human safety database is small but unremarkable for a small, anti-inflammatory tripeptide.
Contraindications: pregnancy, lactation, known hypersensitivity. Use under physician supervision.
Off-label use through a licensed 503A pharmacy.
Who it's typically considered for
- Patients with IBD-spectrum or chronic gut inflammation (specialist-supervised, complementary to standard care)
- Patients with mast cell activation syndrome or histamine-driven symptoms
- Adults with chronic inflammatory skin conditions
- Patients seeking a small-peptide anti-inflammatory adjunct
Frequently asked questions
Is KPV FDA-approved?
No. KPV is investigational; compounded preparations are dispensed by licensed 503A pharmacies under physician prescription for off-label use.
KPV vs BPC-157 for gut?
Different mechanisms. KPV downregulates inflammatory cytokines through NF-κB inhibition. BPC-157 supports epithelial integrity and angiogenesis. They're commonly combined for gut indications.
Will KPV affect my skin pigmentation?
No. KPV lacks the melanogenic activity of intact α-MSH — that's the entire reason the C-terminal fragment is preferred for anti-inflammatory use.
Can KPV replace my IBD medication?
No. KPV is investigational and should be considered a possible adjunct to — not replacement for — physician-directed IBD therapy.
Is oral KPV absorbed?
Yes. KPV is small enough to be absorbed intact through the PEPT1 transporter on intestinal epithelial cells, where it can exert direct anti-inflammatory action in the gut wall.
Does KPV help with MCAS?
KPV's mast cell modulation mechanism is mechanistically aligned with MCAS support. Direct RCT data is limited; specialist-supervised trials are appropriate.
How quickly does KPV work?
Effects on inflammation-driven symptoms typically build over 2–6 weeks of consistent dosing. Faster effects on acute flares have been reported but are individual.
Sources
- Kannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases (2008). — pubmed.ncbi.nlm.nih.gov/18338782
- Brzoska T et al. α-Melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects. Endocrine Reviews (2008). — pubmed.ncbi.nlm.nih.gov/18579753
- Dalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology (2008). — pubmed.ncbi.nlm.nih.gov/18242211
Considering KPV?
A Kindr Health physician reviews every longevity intake — peptides are prescribed only when medically indicated based on your history and labs. There is no charge for the initial review.
Start your longevity intake →Related peptides
Medically reviewed by Dr. Ana Lisa Carr, MD, MBA
Board-Certified Family Medicine Physician · Lead Provider / Medical Reviewer
NPI 1689841744 · Last reviewed: May 10, 2026
Last reviewed May 10, 2026. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products. Prescriptions require a clinical evaluation; a Kindr Health physician determines eligibility. Not for use in pregnancy. This page provides educational information and is not medical advice.